Cytochroma Announces Appointment of Peter Moldt to Board of Directors

30-Nov-2009 - Canada

Cytochroma announced the appointment of Peter Moldt, PhD to its Board of Directors. Dr. Moldt will replace Mr. Ulrik Spork as the Novo A/S representative on the Company's Board. The number of Board members remains unchanged at six members.

Dr. Moldt has experience in corporate strategy, company operations, and drug development. He was most recently CEO of Curalogic A/S, a company he cofounded in 2004 and subsequently took public. Before Curalogic A/S, he was Chief Operating Officer of 7TM Pharma A/S, a company which he cofounded in 2000. Prior to 2000, Dr. Moldt spent 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development. Dr. Moldt holds a PhD in medicinal chemistry from the Royal Danish School of Pharmacy, and has been a post-doc with Yale University's Department of Organic Chemistry.

Other news from the department people

Most read news

More news from our other portals

So close that even
molecules turn red...